SLE Treatment Compound Modulating Autoantibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for systemic lupus erythematosus (SLE) often rely on NSAIDs, low-potency immunosuppressants, and corticosteroids, which may not adequately manage the disease, particularly in severe cases, and there is a need for prophylactic or therapeutic drugs that can effectively treat or prevent SLE.
Innovation Solution
Administration of a therapeutically effective amount of Compound I, specifically (S)-3-[4-(4-morpholin-4-ylmethylbenzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]piperidine-2,6-dione, or its pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, or racemic mixtures, over a period of 56 days, which targets immune response dysregulation and autoantibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (NSAIDs, low-potency immunosuppressants, corticosteroids) are used for SLE, then the treatment approach is simple and well-established, but the therapeutic efficacy is insufficient for severe cases and prophylactic needs
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of existing immunosuppressive agents to create Compound I with enhanced therapeutic properties. The specific molecular modifications result in a compound that provides superior therapeutic efficacy for SLE while maintaining manageable treatment protocols, directly resolving the contradiction between efficacy and complexity
2Reliability
If more potent immunosuppression is used to treat severe SLE, then therapeutic efficacy improves, but side effects and treatment risks increase
Solution Approach 1:
The patent applies local quality by designing Compound I to selectively target pathological immune responses in SLE while sparing normal physiological functions. The compound demonstrates preferential activity against disease-related immune pathways, achieving effective disease control with reduced impact on healthy tissues, thereby resolving the contradiction between disease control and side effects
3Reliability
If prophylactic treatment is implemented for SLE, then disease prevention is improved, but the need for long-term medication increases
Solution Approach 1:
The patent applies continuity of useful action by developing Compound I with pharmacokinetic properties that maintain sustained therapeutic levels in the body. The compound's prolonged half-life and consistent bioavailability enable effective prophylactic treatment with less frequent dosing, addressing the contradiction between disease prevention and treatment duration by making long-term therapy more practical and manageable
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.